HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stabin, M. G. Articles by Breitz, H. B. Search for Related Content PubMed PubMed Citation Articles by Stabin, M. G. Articles by Breitz, H. B.

Breast Milk Excretion of Radiopharmaceuticals: Mechanisms, Findings, and Radiation Dosimetry^*

Departamento de Energia Nuclear, Universidade Federal de Pernambuco, Recife, Brazil
Department of Nuclear Medicine, Virginia Mason Medical Center, Seattle, Washington

Correspondence: For correspondence or reprints contact: Michael Stabin, PhD, CHP, Departamento de Energia Nuclear, UFPE, Av. Prof. Luiz Freire, 1000-Cidade Universitaria, CEP 50740-540, Recife PE, Brazil.

ABSTRACT

The excretion of radiopharmaceuticals in breast milk is studied to understand excretion mechanisms and to determine recommended breast feeding interruption times for many compounds based on the radiation absorbed dose estimated. A literature review is summarized, providing information on breast milk excretion of many radiopharmaceuticals, including the observed fractions of administered activity excreted and the disappearance half-times. Radiation doses to the infant and to the mother's breasts have been calculated using mathematical models of the activity clearance into milk, with interruption schedules for the nursing infant derived using a dose criteria of 1 mSv effective dose to the infant. In only 9 of the 25 radiopharmaceuticals considered here is interruption in breast feeding thought necessary. However, in the literature, breast milk concentrations of radiopharmaceuticals and half-times varied considerably between subjects, and individual measurements are encouraged to raise confidence in specific cases. The absorbed dose to the mother's breast approaches 10–20 mGy (1–2 rad) for a few nuclides, but most doses are quite low. Therapeutic administration of ¹³¹I-Nal is a special case, for which the breast dose for a 5550 MBq (150 mCi) administration could approach 2 Gy (200 rad). In this article, these data are discussed, with the aim of assisting others in evaluating the significance of administration of radiopharmaceuticals to lactating women. An example of a sampling scheme and calculation to determine dose for a specific patient is also developed.

Key Words: dosimetry • breast • radiopharmaceuticals

FOOTNOTES

^* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ARTICLE ON THE SNM WEB SITE (http://www.snm.org) UNTIL NOVEMBER 2000.

This article has been cited by other articles:

				S. A. Gulec and J. A. Siegel Posttherapy Radiation Safety Considerations in Radiomicrosphere Treatment with 90Y-Microspheres J. Nucl. Med., December 1, 2007; 48(12): 2080 - 2086. [Abstract] [Full Text] [PDF]

				T Kogai, K Taki, and G A Brent Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 797 - 826. [Abstract] [Full Text] [PDF]

				D. Vranjesevic, C. Schiepers, D. H. Silverman, A. Quon, J. Villalpando, M. Dahlbom, M. E. Phelps, and J. Czernin Relationship Between 18F-FDG Uptake and Breast Density in Women with Normal Breast Tissue J. Nucl. Med., August 1, 2003; 44(8): 1238 - 1242. [Abstract] [Full Text] [PDF]

				R. J. Hicks, D. Binns, and M. G. Stabin Pattern of Uptake and Excretion of 18F-FDG in the Lactating Breast J. Nucl. Med., August 1, 2001; 42(8): 1238 - 1242. [Abstract] [Full Text] [PDF]